World's Best Scientists 2026 revealed!
Markolf Hanefeld

Markolf Hanefeld

D-Index & Metrics

Medicine

D-Index
85
Citations
37846
World Ranking
14398
National Ranking
763

Markolf Hanefeld publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Markolf Hanefeld sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 436 publications — 46th percentile

46% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Markolf Hanefeld D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Markolf Hanefeld sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 85 D-Index — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Markolf Hanefeld is a researcher affiliated with TU Dresden in Germany, primarily working in the field of medicine with a focus on endocrinology, diabetes, and metabolism. Their research encompasses topics such as diabetes treatment and management, pharmacology and obesity treatment, metabolism in connection to diabetes and cancer, hormonal and reproductive studies, diabetes management and research, lipoproteins and cardiovascular health, and neuropeptides and animal physiology.

Hanefeld has contributed to several recent publications, including:

  • The effect of dulaglutide on stroke: an exploratory analysis of the REWIND trial, 2020, published in The Lancet Diabetes & Endocrinology
  • The Current and Potential Therapeutic Use of Metformin-The Good Old Drug, 2021, published in Pharmaceuticals
  • Remission of type 2 diabetes following long-term treatment with injectable testosterone undecanoate in patients with hypogonadism and type 2 diabetes: 11-year data from a real-world registry study, 2020, published in Diabetes Obesity and Metabolism
  • Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update, 2020, published in Diabetes Therapy
  • Erectile function in men with type 2 diabetes treated with dulaglutide: an exploratory analysis of the REWIND placebo-controlled randomised trial, 2021, published in The Lancet Diabetes & Endocrinology

Their frequent coauthors include Andreas L. Birkenfeld, Hertzel C. Gerstein, Helen M. Colhoun, Mark Lakshmanan, and Jeffrey L. Probstfield.

Hanefeld has published multiple works in venues such as:

  • The Lancet Diabetes & Endocrinology
  • Diabetologie und Stoffwechsel
  • Pharmaceuticals
  • Diabetes Obesity and Metabolism
  • Diabetes Therapy

The researcher's work spans several subfields, including pharmacology and surgery, and incorporates elements of molecular biology and cardiology. Overall, Markolf Hanefeld's body of work centers predominantly around diabetes and its treatment modalities, with a multidisciplinary approach linking metabolic processes and cardiovascular as well as hormonal functions.

Best Publications

  • Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial.

    Jean-Louis Chiasson;Robert G Josse;Ramon Gomis;Markolf Hanefeld

  • Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial.

    Jean-Louis Chiasson;Robert G. Josse;Ramon Gomis;Markolf Hanefeld

  • Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial.

    rosiglitazone Medication Trial Investigators;H C Gerstein;S Yusuf

  • Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial

    Philip D. Home;Stuart J. Pocock;Henning Beck-Nielsen;Paula S. Curtis

  • Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up.

    M. Hanefeld;S. Fischer;U. Julius;J. Schulze

  • Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis.

    Philip D. Home;Stuart J. Pocock;Henning Beck-Nielsen;Ramón Gomis

  • Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies.

    M. Hanefeld;M. Cagatay;T. Petrowitsch;D. Neuser

  • Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level.

    Theodora S. Temelkova-Kurktschiev;Carsta Koehler;Elena Henkel;Wolfgang Leonhardt

  • Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy.

    D Ziegler;M Hanefeld;K J Ruhnau;H Hasche

  • Postprandial Glucose Regulation and Diabetic Complications

    Antonio Ceriello;Markolf Hanefeld;Lawrence Leiter;Louis Monnier

  • Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study

    David Russell-Jones;Robert M. Cuddihy;Markolf Hanefeld;Ajay Kumar

  • Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial

    G. Schernthaner;D. R. Matthews;B. Charbonnel;M. Hanefeld

  • Acarbose Slows Progression of Intima-Media Thickness of the Carotid Arteries in Subjects With Impaired Glucose Tolerance

    Markolf Hanefeld;Jean Louis Chiasson;Carsta Koehler;Elena Henkel

  • In type 2 diabetes, rosiglitazone therapy for insulin resistance ameliorates endothelial dysfunction independent of glucose control.

    Frank Pistrosch;Jens Passauer;Sabine Fischer;Katja Fuecker

  • One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.

    Markolf Hanefeld;Paolo Brunetti;Guntram H Schernthaner;David R Matthews

  • Insulin Secretion and Insulin Sensitivity Pattern Is Different in Isolated Impaired Glucose Tolerance and Impaired Fasting Glucose: The Risk Factor in Impaired Glucose Tolerance for Atherosclerosis and Diabetes Study

    Markolf Hanefeld;Carsta Koehler;Katja Fuecker;Elena Henkel

  • The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.

    Emile R. Mohler;Christie M. Ballantyne;Michael H. Davidson;Markolf Hanefeld

  • Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals.

    M. Hanefeld;C. Koehler;F. Schaper;K. Fuecker

  • Heart failure events with rosiglitazone in type 2 diabetes: data from the RECORD clinical trial

    Michel Komajda;John J.V. McMurray;Henning Beck-Nielsen;Ramon Gomis

  • Acarbose Treatment and the Risk of Cardiovascular Disease and Hypertension in Patients With Impaired Glucose Tolerance

    Jean-Louis Chiasson;Robert G. Josse;Markolf Hanefeld;Markku Laakso

Frequent Co-Authors

Patrick A. Ott
Patrick A. Ott Harvard University
Hertzel C. Gerstein
Hertzel C. Gerstein McMaster University
Antonio Ceriello
Antonio Ceriello MultiMedica
David R. Owens
David R. Owens Cardiff University
Guntram Schernthaner
Guntram Schernthaner Medical University of Vienna
Henning Beck-Nielsen
Henning Beck-Nielsen Odense University Hospital
Stuart J. Pocock
Stuart J. Pocock London School of Hygiene & Tropical Medicine
Philip Home
Philip Home Newcastle University
Markku Laakso
Markku Laakso University of Eastern Finland

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The medical field offers a wide range of alternative online degrees and career pathways for those interested in healthcare, beyond becoming a physician. Many prospective students are drawn to direct entry msn programs, which allow those without a nursing background to earn a Master of Science in Nursing, opening doors to advanced practice roles in less time.

For those starting their journey, online adn programs for non nurses provide a fast and flexible pathway to become a registered nurse, with accessible admission requirements and a shorter timeline compared to traditional routes.

Not everyone in healthcare works on the frontlines. Administrative roles, such as medical coder or biller, are crucial and in demand. Many institutions offer medical coding and billing classes online with financial aid, making it easier to break into the field without incurring significant debt.

Admission testing can be a barrier for some. Fortunately, several schools do not require applicants to sit for exams like the TEAS or HESI. If you're wondering, do you have to take the teas test to get into nursing school, you'll find options that waive these requirements—making nursing education more accessible.

Best Scientists Citing Markolf Hanefeld

Trending Scientists

Recently Published Articles